Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Peng Peng
TransThera Sciences (Nanjing), Inc.
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
38
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Tinengotinib for Adult Patients with Advanced or Metastatic Cholangiocarcinoma: A Multicenter, Open-Label Phase 2 Trial
Number of pages: 49
Posted: 25 Mar 2025
Milind Javle
,
Christos Fountzilas
,
Chih-Yi (Andy) Liao
,
Meredith Pelster
,
Daneng Li
,
Dustin Deming
,
Vaibhav Sahai
,
Lionel Aurelien Kankeu Fonkoua
,
Allen Cohn
,
Parvez Mantry
,
Donald Richards
,
Edwin Kingsley
,
Frank Wu
, Peng Peng,
Katie Hennessy
,
Angie Sun
,
Shumao Ni
,
Jean Fan
and
Amit Mahipal
University of Texas at Houston - MD Anderson Cancer Center, Roswell Park Comprehensive Cancer Center - Department of Medicine, University of Chicago - Division of Biological Sciences, Sarah Cannon Research Institute, City of Hope - Comprehensive Cancer Center, University of Wisconsin-Madison, University of Michigan at Ann Arbor, Mayo Clinic College of Medicine and Science, Rocky Mountain Cancer Centers, Methodist Dallas Medical Center, Texas Oncology, Comprehensive Cancer Centers of Nevada, TransThera Sciences (Nanjing), Inc., TransThera Sciences (Nanjing), Inc., TransThera Sciences (Nanjing), Inc., TransThera Sciences (Nanjing), Inc., TransThera Sciences (Nanjing), Inc., TransThera Sciences (Nanjing), Inc. and University Hospitals Cleveland Medical Center, Seidman Cancer Center
Downloads
38
(950,723)
View PDF
Download
Abstract:
cholangiocarcinoma, intrahepatic, FGFR, FGFR2, FGFR inhibotor
Feedback